4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001209191-23-012015
Chief Executive Officer sold 32,861 shares at $4.66 ($153,132)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ballal Rahul D. Chief Executive Officer | 2023-02-22 | Sale | −32,861 | $4.66 | $153,132 | 87,835 | D: show line 1 in the form |
| Open-market sales · 32,861 sh · avg $4.66 · $153,132 | |||||||
Loading xslF345X03/doc4.xml…